Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 206-137-4 | CAS number: 303-26-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction: other studies
Administrative data
- Endpoint:
- toxicity to reproduction: other studies
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data from peer reviewed journal
Data source
Reference
- Reference Type:
- publication
- Title:
- Production of Fetal Rat Malformations by - Norchlorcyclizine and Chlorcyclizine after Intrauterine application
- Author:
- A. L. WILK
- Year:
- 1 969
- Bibliographic source:
- Teratology Vol 2, Is 1, PP 55-65, feb 1969
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: As mentioned below
- Principles of method if other than guideline:
- To evaluate the teratologic potential of Norchlorcyclizine, in female Sprague-Dawley pregnant rats after Intrauterine application.
- GLP compliance:
- not specified
- Type of method:
- in vivo
Test material
- Reference substance name:
- N-(4-chlorobenzhydryl)piperazine
- EC Number:
- 206-137-4
- EC Name:
- N-(4-chlorobenzhydryl)piperazine
- Cas Number:
- 303-26-4
- Molecular formula:
- C17H19ClN2
- IUPAC Name:
- N-(4-chlorobenzhydryl)piperazine
- Test material form:
- solid
- Details on test material:
- - Name of the test material: 1-[(4-chlorophenyl)(phenyl)methyl]piperazine
- Common Name: Norchlorcyclizine
- IUPAC name: 1-[(4-chlorophenyl)(phenyl)methyl]piperazine
- Molecular weight: 286.804 g/mol
- Molecular formula: C17H19ClN2
- Substance type: Organic
- SMILES Notation: c1([C@@H](c2ccccc2)N2CCNCC2)ccc(Cl)cc1
- InChI: 1S/C17H19ClN2/c18-16-8-6-15(7-9-16)17(14-4-2-1-3-5-14)20-12-10-19-11-13-20/h1-9,17,19H,10-13H2
- Physical State: Solid (white to pale yellow)
Constituent 1
- Specific details on test material used for the study:
- - Name of the test material: 1-[(4-chlorophenyl)(phenyl)methyl]piperazine
- IUPAC name: 1-[(4-chlorophenyl)(phenyl)methyl]piperazine
- Molecular weight: 286.804 g/mol
- Molecular formula: C17H19ClN2
- Substance type: Organic
- Smiles: c1([C@@H](c2ccccc2)N2CCNCC2)ccc(Cl)cc1
- Inchi: 1S/C17H19ClN2/c18-16-8-6-15(7-9-16)17(14-4-2-1-3-5-14)20-12-10-19-11-13-20/h1-9,17,19H,10-13H2
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Details on test animal
TEST ANIMALS
- Source: No data available.
- Age at study initiation: (P) x wks; (F1) x wks
- Weight at study initiation: Females:200 grams
- Fasting period before study: - No data available.
- Housing: - No data available.
- Diet (e.g. ad libitum): No data available.
- Water (e.g. ad libitum): No data available.
- Acclimation period: No data available
ENVIRONMENTAL CONDITIONS
No data available.
Administration / exposure
- Route of administration:
- other: intrauterine application
- Vehicle:
- other: HCl
- Details on exposure:
- Details on exposure
Millipore filters (HA 0.45µ) were cut into strips 4 X 0.2 cm and then dipped into 0.01 ml of aqueous solutions containing 50 µg/ filter squares concentrations of norchlorcyclizine HCl. The filter strip completely absorbed this volume and was dried under a stream of air. The strip was placed on a mold of the same dimensions, which was marked into 20 squares each measuring 0.2 X 0.2 cm and the filter strip was cut into squares. and implanted over the fetal side or placenta on day 13 of gestation - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- In order to test for variation in the concentration of the compounds in the individual filter squares each square was placed in 1 ml of IN HC1 and the acid extracted compound read at 230 m µ in a spectrophotometer. An expected concentration of 50 or 90 µ g had a maximum variation of ± 10 µg. Filter squares similarly prepared with stoichiometric amounts of HCl were used as controls
- Duration of treatment / exposure:
- on days 11-16 of gestation days
- Frequency of treatment:
- on days 11-16 of gestation days
- Duration of test:
- on days 11-20 of gestation days
Doses / concentrations
- Remarks:
- 50µg(0.05mg/filter ),90µg(0.09mg/filter )
- Control animals:
- yes, concurrent vehicle
Results and discussion
Effect levels
- Dose descriptor:
- LOAEL
- Effect level:
- 0.05 other: mg/filter
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- body weight and weight gain
- gross pathology
- other: malformation like Cleft palate and limb abnormalities
- Remarks on result:
- other: Developmental effects observed
Observed effects
Any other information on results incl. tables
Effectofintrauterine surgical procedureonmaternalandfetal weights
Day and treatment |
No. of pregnant rats |
Mean maternal wt gain between day 13-20 (g ±S.E) |
No of fetuses |
Mean wt. Of day-20 fetuses (g ±S.E) |
None |
8 |
68 ±5.6 |
58 |
3.9 ±0.05 |
13 HCl control (F.S.)* |
25 |
20± 3.0 |
95 |
3.2 ±0.10 |
13 Nor CC(F.S.)** |
30 |
28 ±4.2 |
130 |
3.2 ± 0.10 |
13 Nor CC(P.S.)* |
21 |
28 ± 5.4 |
102 |
3.4 ±0.05 |
*Filters placed over the fetal side (F.S.); over the placenta(P.S.).
**Nor CC=norchlorcyclizine HCI, approx. 50 µg/filter.
Malformations produced aftez norchlmcyclizineHCZor HCl filter insertion on the fetal side over the headorthe left hindlimb
Day and treatment |
Position of filter |
No. of site treated |
Survival |
Cleft palate |
% limb malformed * |
||
Left Hind limb |
Right hind limb |
Left fore limb |
|||||
14 HCl |
Head |
60 |
32 |
0 |
0 |
0 |
0 |
14 Nor CC (50µg/filter ) |
Head |
85 |
36 |
42 |
13 |
3 |
3 |
14 Nor CC (50µg/filter ) |
Hind limb |
128 |
46 |
11 |
55 |
2 |
4 |
15 HCl |
Head |
35 |
90 |
0 |
0 |
0 |
0 |
15 Nor CC (50µg/filter |
Head |
78 |
83 |
3 |
0 |
0 |
0 |
*Right forelimb never malformed
Malformations produced following central insertion of compound-impregnated millipore filters
Day and treatment |
No. of site treated |
Survival (%) |
Cleft palate (%) |
Left forelimb* malformed (%) |
11 HCl |
31 F.S.** |
80 |
0 |
0 |
11 Nor CC |
48 F.S. |
81 |
0 |
0 |
12 HCl |
45 F.S. |
93 |
0 |
0 |
12 Nor CC |
135 F.S. |
71 |
0 |
0 |
13 HCl |
128 F.S. |
74 |
0 |
0 |
13 Nor CC |
200 F.S. |
65 |
29 |
24 |
13 Nor CC(90µg/filter ) |
63 F.S. |
6 |
75 |
75 |
14HCl |
85 F.S. |
42 |
0 |
0 |
14 Nor CC |
72 F.S. |
46 |
35 |
38 |
15 HCl |
65 F.S. |
66 |
0 |
0 |
15 Nor CC(90µg/filter ) |
79 F.S. |
84 |
0 |
2 |
16 HCl |
58 F.S. |
74 |
0 |
|
16 Nor CC(90µg/filter ) |
89 F.S. |
74 |
0 |
3 |
*The left forelimb was the only limb malformed following central insertion.
**Filters placed over the fetal side (F.S.); over the placenta(P.S.).
NorCC, norchlorcyclizine HC1. approx. 50µg/filter, unless noted otherwise
Applicant's summary and conclusion
- Conclusions:
- LOAEL was considered to be 0.05mg/kg/day on the bases of teratognic potential . When female Sprague-Dawley rats were exposed with Norchlorcyclizine (303-26-4) through the 11-16 day of gestation after Intrauterine application
- Executive summary:
The teratognicity of Norchlorcyclizine (303-26-4)was studied in female Sprague-Dawley rats when they were exposed through the 14-15 day of gestation after Intrauterine applicationof test material.In this technique of intrauterine application a compound, which by passes the metabolism of the adult rat and directly subjects the fetus to microgram concentrations of the compound for a known period of time. Pregnant Sprague-Dawley rats were used on days 11-16 of gestation. Vaginal smears were taken to determine pregnancy with the appearance of sperm designated as day 0 of gestation. Semisterile operational procedure was followed. Animals weighing approximately 200 g were anesthetized with an intraperitoneal injection of1ml of a 10% pentobarbital sodium solution supplemented, when necessary, with light ether inhalation. A midline abdominal incision was made and the double horned uterus was exteriorized.Asmall cut was then made through the uterine wall and a Millipore filter square impregnated with norchlorcyclizine HCl, or HCl was inserted either on the yolk sac over the intact amniotic sac (fetal side) or on the placenta .Once inserted, the filters remained in place until after day 16 when fetal movements seemed to dislodge them. In each pregnant rat, fetuses in one uterine horn were usually subjected to experimental filters and the HCl-containing, control filter was placed over fetuses in the other horn. Prior to day 14 of gestation the position of the embryo cannot be seen through the uterus and the filters were always inserted centrally over the fetus. On days 14 and 15 it was possible to insert the filters centrally, over the hindlimb, or over the head area .All fetuses observed on days 14, 15, and 16 appeared to lie with their left side uppermost and the right side toward the placenta. After these uterine manipulations the uterus was returned to the abdominal cavity, the muscle layer sutured, and the skin clamped with stainless steel clips. The animal was then placed on its back in a warm recovery area and when it recovered from the anesthesia it was returned to the animal room and gestation was allowed tocontinue to day 20.Pregnant rats were weighed and killed on day 20 and the young removed.
Gross malformations were noted by observation and the fetuses were weighed and then placed in 80% ethanol. After alcohol fixation the fetuses were cleared of most soft tissue with 1% KOH and stained with 0.5% alizarin redS.The stained specimens were examined for skeletal malformations. The effect of the surgical procedure on the maternal weight gain from days 13-20 and on the fetal weight on day 20. Postoperational survival of pregnant rats was excellent. Pregnant operated rats gained approximately one-third as much weightasdid unoperated pregnant animals and operated fetuses had a mean weight of about 3.3g on day 20while that of unoperated fetuses was 3.9 g. Fetal survival after surgery and insertion of HCl-containing filters was over 60% on every day except day 14 when it was approximately 42%. Cleft palate was produced at rates of 29 and 35% after norchlorcyclizine (50ug/filter) was inserted centrally on the fetal side on day 13 or 14 respectively. When the concentration of norchlorcyclizine was increased to 90 or 100 ug/filter and implanted centrally or over the head area of fetuses on day 15, less than 3% cleft palate was observed. Another malformation frequently seen following intrauterine application of norchlorcyclizine, was a limb malformation, which affected either the left forelimb or left hindlimb depending on whether the filter was placed centrally or over the hindlimb area of the fetus. The severity of the malformation ranged from simple fusion of the digits to complete absence of a paw. Left forelimb anomalies occurred at a rate of 24 and 38% after norchlorcyclizine (50 ug/filter) was inserted centrally on day 13 or 14 respectively and at a rate of about 3% after norchlorcyclizine- filter insertion on day 11, 12, 15, or 16Apositive relation between filter position over the fetus and cleft palate production was also found .When norchlorcyclizine (50 ug/filter) was inserted over the head area on the fetal side 42% of the fetuses had cleft palates and 13% had hindlimb malformations. Filters with similar concentration of norchlorcyclizine inserted over the left hind limb, however, resulted in 11% cleft palate and 55% left hind limb malformation. Gross observation of whole and cleared fetuses showed that the heads of some fetuses treated with test material filters were misshapen and the bodies more squat than normal.The control filters produced no malformation when implanted on any of the experimental days. Similarly no abnormalities resulted after norchlorcyclizine-filter insertion over the placenta on day 13.Hence LOAEL was considered to be 0.05mg/kg/day on the bases of teratognic potntional. WhenfemaleSprague-Dawley rats were exposed withNorchlorcyclizine (303-26-4)through the 13-14 day of gestationafter Intrauterine application
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.